Related Experiment Video
Updated: Jul 21, 2025
Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer
Published on: March 14, 2019
LncRNA FTH1P3: A New Biomarker for Cancer-Related Therapeutic Development
1Department of Medical Biotechnology, School of Medicine, Arak University of Medical Sciences, Arak, Iran.
Abstract:
Cancer is a persistent and urgent health problem that affects the entire world. Not long ago, regulatory biomolecules referred to as long noncoding RNAs (lncRNAs) might have value for their innate abundance and stability. These single-stranded RNAs potentially interfere with several physiological and biochemical cellular processes involved in many human pathological situations, particularly cancer diseases. Ferritin heavy chain1 pseudogene 3 (FTH1P3), a lncRNA that is ubiquitously transcribed and belongs to the ferritin heavy chain (FHC) family, represents a novel class of lncRNAs primarily found in oral squamous cell carcinoma. Further research has shown that FTH1P3 is involved in other malignancies such as uveal melanoma, glioma, esophageal squamous cell carcinoma, non-small cell lung cancer, breast cancer, laryngeal squamous cell carcinoma, and cervical cancer. Accordingly, FTH1P3 significantly enhances cancer symptoms, including cell proliferation, invasion, metastasis, chemoresistance, and inhibition of apoptosis through many specific mechanisms. Notably, the clinical data significantly demonstrated the association of FTH1P3 overexpression with poor prognosis and poor overall survival within the examined samples. Here, we summarize all the research published to date (13 articles) on FTH1P3, focusing on the biological function underlying the regulatory mechanism and its possible clinical relevance.
Insights
Long noncoding RNAs (lncRNAs) like FTH1P3 are increasingly recognized for their role in cancer. This review highlights FTH1P3
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Long noncoding RNAs (lncRNAs) are regulatory molecules with roles in various diseases, including cancer.
- Ferritin heavy chain 1 pseudogene 3 (FTH1P3) is a novel lncRNA identified in oral squamous cell carcinoma and other malignancies.
- FTH1P3's overexpression is linked to adverse clinical outcomes in cancer patients.
Purpose of the Study:
- To review and synthesize current research on the lncRNA FTH1P3.
- To elucidate the biological functions and regulatory mechanisms of FTH1P3 in cancer.
- To discuss the potential clinical relevance of FTH1P3 in cancer diagnosis and prognosis.
Main Methods:
- Systematic literature review of published studies on FTH1P3.
- Analysis of experimental data on FTH1P3's role in cancer cell proliferation, invasion, metastasis, chemoresistance, and apoptosis.
- Examination of clinical data correlating FTH1P3 expression with patient survival and prognosis.
Main Results:
- FTH1P3 is implicated in promoting cancer progression, including enhanced cell proliferation, invasion, and metastasis.
- FTH1P3 contributes to chemoresistance and inhibits apoptosis in various cancer types.
- Overexpression of FTH1P3 is significantly associated with poor prognosis and reduced overall survival.
Conclusions:
- FTH1P3 is a critical oncogenic lncRNA with a significant role in multiple human cancers.
- Understanding FTH1P3's mechanisms may lead to novel therapeutic strategies and biomarkers for cancer.
- Further research into FTH1P3 is warranted to explore its full clinical potential.
Related Concept Videos
02:39lncRNA - Long Non-coding RNAs
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
03:18Non-LTR Retrotransposons